Evaluation of Pcv-aCO2 in the Fluid Treatment of Abdominal Tumor Patients After Surgery

Tianjin Medical University Cancer Institute and Hospital150 enrolled

Overview

This research will confirm that Pcv-aCO2 is suitable for the guidance of early fluid therapy and the evaluation of the prognosis of patients with abnormal hemodynamics after abdominal tumor surgery, and is expected to be a new monitoring index to improve the therapeutic effect of these patients.

1. Confirmed that Pcv-aCO2 is suitable for the guidance of early fluid therapy and the evaluation of the prognosis of patients with abnormal hemodynamics after abdominal tumor surgery, and is expected to be a new monitoring index to improve the therapeutic efficacy of this kind of patients. 2. Pcv-aCO2 effectively reflected the improvement of tissue and organ microcirculation disorder through the individual goal target treatment to guide the fluid resuscitation in the hemodynamic instability patients. 3. Research of the correlation between Pcv-aCO2 and the organ function in patients with abnormal hemodynamics after operation.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

150

Conditions

Abdominal Tumor Abdominal Infection

Interventions

standardized fluid therapyOTHER

The patients with ScvO2 \<70% will receive the standardized fluid therapy for 6 hours.

conventional fluid therapyOTHER

The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. Acute physiology and chronic health score system II (APACHE II) score ≥10； 2. Hemodynamic abnormalities post-operation (a. systolic blood pressure\<90mmHg, or descent by basic blood pressure for more than 40mmHg. b. pulse pressure \<20mmHg, c. urine volume \<0.5ml/Kg/hr, d. heart rate \>100 / min, e.Central Venous Pressure(CVP) \<5mmHg, f. blood lactic acid \>2.7mmol/L, meet any one above). 3. Age ≥ 18 years, which is expected to stay in ICU for 5 days or longer; 4. Patients themselves or their authorized clients agree to participate in clinical trials and signed informed consent. Exclusion Criteria: 1. age \<18 years; 2. without improvement in respiratory system disease or chronic obstructive pulmonary disease with Forced expiratory volume in one second (FEV1) \<50%; 3. lobectomy and pneumonectomy; 4. death within 24 after treatment; 5. patients with severe organ dysfunction; 6. pregnant or lactating women; 7. the patients did not sign informed consent; 8. any factors that may be expected to increase the risk of patients or other factors that may interfere with the results of clinical trials.

Locations (1)

Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, China

RECRUITING

Outcomes

Primary Outcomes

The change of Pcv-aCO2

The change of Pcv-aCO2 (mmHg) after fluid resuscitation for 6 hours, 12 hours and 24 hours respectively.

Time frame: fluid resuscitation for 6 hours, 12 hours and 24 hours

Secondary Outcomes

The treatment success rate in different groups

Collect the index of treatment success rate(%) of patients in different groups.

Time frame: Twenty-eighth days after admission

The 28 day mortality in different groups

Collect the index of 28 day mortality(%) of patients in different groups.

Time frame: Twenty-eighth days after admission

The hospitalization course in different groups

Collect the index of hospitalization course(days) of patients in different groups.

Time frame: Twenty-eighth days after admission

Central Contacts

Yang Yang, physician

CONTACT

022-23340123 yyicu3021@126.com

Yang Lu, physician

CONTACT

022-23340123 Yang_lu1299@hotmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.